CORDIS
EU research results

CORDIS

English EN
BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Objective

The innovation of the biohybrid and biodegradable nanovaccines to be taken to proof-of-concept lies in the combination of different parts of the nanovaccine. A biohybrid and biodegradable nanovaccine shows potential to: (i) enhance cancer treatment efficacy; (ii) to be universally applicable to all cancers, regardless of the tumour in question; (iii) prolonging the survival rate of cancer patients; (iv) increase the amount of complete tumor remissions; and (v) boost of tumor-specific immune responses. This will allow in the future towards a personalized patient cancer therapy/treatment. More importantly, the applicability of biohybrid and biodegradable nanovaccines extends beyond the cancer treatment, as it can be applied for other type of diseases.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Host institution

HELSINGIN YLIOPISTO

Address

Yliopistonkatu 3
00014 Helsingin Yliopisto

Finland

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 150 000

Beneficiaries (1)

Sort alphabetically

Sort by EU Contribution

Expand all

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 150 000

Project information

Grant agreement ID: 825020

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    30 June 2020

Funded under:

H2020-EU.1.1.

  • Overall budget:

    € 150 000

  • EU contribution

    € 150 000

Hosted by:

HELSINGIN YLIOPISTO

Finland